Inovio Pharmaceuticals (INO): Moving to Phase 3 with First Potential Treatment for HPV Infection of the Cervix

Spotlight Companies |

We've been following a company that has been making demonstrable progress in advancing the science of DNA immunotherapy that activates the body’s immune system to break its tolerance of cancerous cells and protect against diverse, changing strains of infectious diseases. Inovio Pharmaceuticals (NYSE: INO) has developed a platform technology with potentially very broad applicability to target a range of diseases while generating optimal antigen production in the body. Its lead candidate has the potential to be the first available treatment for human papillomavirus (HPV) infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions.


Source: Inovio Pharmaceuticals Corporate Presentation, June 2017


Beginning Phase 3 for HPV-caused cervical dysplasia

Last week, Inovio announced that it had initiated a pivotal phase III study to evaluate the safety and efficacy of its lead candidate, VGX-3100, to treat cervical dysplasia caused by HPV. Current surgical methods do not treat the underlying HPV infection and carry increased risk of cervical incompetence and pre-term birth. This study will consist of primary and confirmatory trials conducted in parallel per the FDA’s guidance. The primary endpoint is regression of cervical high-grade squamous intraepithelial lesions (HSIL) and virologic clearance of HPV-16 and/or HPV-18 in the cervix. Each study will enroll 198 patients across over 100 study centers globally. Inovio also recently initiated a phase II study with VGX-3100 for treating patients with vulvar intraepithelial neoplasia (VIN).


Source: Inovio Pharmaceuticals Corporate Presentation, June 2017

Robust Clinical Pipeline

Inovio's platform technology has spawned a deep clinical pipeline, with five studies that have efficacy endpoints. Additionally, the company has partnered and is collaborating with industry leaders including Medimmune, wholly owned by AstraZeneca (NYSE: AZN), Regeneron (Nasdaq: REGN) and Genentech, wholly owned by Roche(Switzerland: ROG; OTCQX: RHHBY). Inovio also has multiple vaccine programs in early clinical stages, including developmental treatments for HIV, Ebola, MERS and Zika.


Source: Inovio Pharmaceuticals Corporate Presentation, June 2017


Experienced Leadership with Merck Roots



CEO Joseph Kim, PhD, co-founded VGX Pharmaceuticals, a synthetic vaccine company, in 2000 to develop intellectual property related to immunotherapeutics licensed from the University of Pennsylvania. He led that company for nine years and combined VGX with Inovio Biomedical in 2009 to form Inovio Pharmaceuticals. Previously, Dr. Kim was a senior vaccine developer at Merck & Co. where he successfully led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV/AIDS.

The board of directors includes the former president of Merck Vaccines (NYSE: MRK) a former SVP at Merck Vaccines and the EVP of the Vaccine Center. The scientific advisory board includes thought leaders in vaccines, DNA vaccines and electroporation.


The stock trades actively on the NYSE MKT, with average daily volume of 1.5 million shares and a market cap of $580 million. Current revenues ($38 million over the last 12 months) are derived from collaborative R&D arrangements and grants. We'll be keeping close tabs on Inovio Pharmaceuticals, as its broad pipeline should manifest in numerous milestone achievements this year and going forward.




Please email us at content@equities.com if you are a Public Company and would like to see our Case Studies or Testimonials.

Please click here if you would like information on our new trading platform.

Please click here if you're an investor and would like to see our weekly newsletter.


In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
INO Inovio Pharmaceuticals Inc. 5.55 -0.01 -0.18 738,138 Trade
AZN Astrazeneca PLC 29.14 0.07 0.24 2,443,287 Trade
MRK Merck & Company Inc. (new) 62.15 -0.27 -0.43 6,434,881 Trade
REGN Regeneron Pharmaceuticals Inc. 477.15 -1.50 -0.31 410,585 Trade
RHHBY Roche Holding Ltd ADR (Sponsored) 31.41 -0.05 -0.16 983,277

Comments

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

California Green Tree Development

California Green Tree Development LLC (CGTD) is a for-profit LLC that plans on using California’s booming market of legal cannabis products for medical purposes. As an unprecedented resource, Cannabis has…